Today’s expectations
Are your treatment expectations in ITP being driven by compromise?
When corticosteroid treatment is no longer sufficient or suitable for patients with ITP, TPO-RAs are recommended for long-term platelet control1–2 – but treatment decisions often involve making compromises.3–9
Treatment failure, lack of sustained efficacy or inadequate platelet control may compromise treatment goals3
Subcutaneous administration may require regular clinic visits and go against patient preference for oral treatment7-9
When it comes to TPO-RA selection,
what matters most to your patients?
Explore what Doptelet can offer
Doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).10
Doptelet is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.10
ITP, immune thrombocytopenia; TPO-RA, thrombopoietin receptor agonist.
References
1.. Neunert CE et al. Blood Adv. 2019; 3(23):3829–3866. 2. Provan D et al. Blood Adv. 2019; 3(22):3780–3817. 3. Cantoni S et al. Am J Hematol. 2018; 93(1):58–64. 4. Cheloff AZ and Al-Samkari H. J Blood Med. 2019; 10:313–321. 5. Tsykunova G and Ghanima W. Ther Clin Risk Manag. 2022; 18:273–286. 6. Revolade Summary of Product Characteristics. 05/2023. 7. Kuter DJ et al. Am J Hematol. 2020; 95(6): 643–651. 8. McDonald V et al. Hematology. 2021; 26(1): 799–808. 9. Nplate Summary of Product Characteristics. 10/2022. 10. Doptelet Summary of Product Characteristics. 22/05/2025